EUVIMEDEUVIMED entdecken
Multizentrische Studie

3-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study

Firas Zahr, Basel Ramlawi, Michael J Reardon, G Michael Deeb, Steven J Yakubov, Howard K Song, Neal S Kleiman, Stanley J Chetcuti, Hemal Gada, Mubashir Mumtaz, Stephane Leung, William Merhi und 8 weitere

JACC: Cardiovascular Interventions · 2024

DOI: 10.1016/j.jcin.2024.05.017 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2024. Verfasst von Firas Zahr und 19 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Health & Science University, Portland, Oregon, USA. Electronic address: zahr@ohsu.edu. Hauptthemen laut MEDLINE: Bicuspid Aortic Valve Disease, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Medtronic Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Outcomes from transcatheter aortic valve replacement (TAVR) in low-surgical risk patients with bicuspid aortic stenosis beyond 2 years are limited. OBJECTIVES: This study aimed to evaluate 3-year clinical and echocardiographic outcomes from the Evolut Low Risk Bicuspid Study. METHODS: The Evolut Low Risk Bicuspid Study is a prospective, multicenter, single-arm study conducted in 25 U.S. CENTERS: Patients with severe aortic stenosis at low surgical risk with bicuspid aortic valve anatomy (all subtypes) underwent TAVR with a self-expanding, supra-annular Evolut R or PRO (Medtronic) bioprosthesis. An independent clinical events committee adjudicated all deaths and endpoint-related adverse events, and a central echocardiographic core laboratory assessed hemodynamic endpoints. RESULTS: An attempted implant was performed in 150 patients from December 2018 to October 2019. The mean age was 70.3 ± 5.5 years, 48% (72/150) of the patients were women, and the mean Society of Thoracic Surgeons Predicted Risk of Mortality score was 1.3% (Q1-Q3: 0.9%-1.7%). Sievers type 1 was the dominant bicuspid morphology (90.7%, 136/150). The Kaplan-Meier rates of all-cause mortality or disabling stroke were 1.3% (95% CI: 0.3%-5.3%) at 1 year, 3.4% (95% CI: 1.4%-8.1%) at 2 years, and 4.1% (95% CI: 1.6%-10.7%) at 3 years. The incidence of new permanent pacemaker implantation was 19.4% (95% CI: 12.4%-29.6%) at 3 years. There were no instances of moderate or severe paravalvular aortic regurgitation at 2 and 3 years after TAVR. CONCLUSIONS: The 3-year results from the Evolut Low Risk Bicuspid Study demonstrate low rates of all-cause mortality or disabling stroke and favorable hemodynamic performance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bicuspid Aortic Valve DiseaseTranscatheter Aortic Valve ReplacementAgedAged, 80 and overFemaleHumansMaleMiddle AgedAortic ValveAortic Valve StenosisBioprosthesisHeart Valve DiseasesHeart Valve ProsthesisHemodynamicsPostoperative ComplicationsProspective StudiesProsthesis DesignRecovery of FunctionRisk AssessmentRisk FactorsSeverity of Illness IndexTime Factors

Stichwörter der Autor:innen

Evolut PROEvolut RSievers typebicuspid aortic valvestranscatheter aortic valve replacement

Autor:innen und Institutionen

  • Oregon Health & Science University, Portland, Oregon, USA. Electronic address: zahr@ohsu.edu.
  • Lankenau Heart Institute, Philadelphia, Pennsylvania, USA.
  • Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA.
  • University of Michigan Health Systems, University Hospital, Ann Arbor, Michigan, USA.
  • OhioHealth Riverside Methodist Hospital, Columbus, Ohio, USA.
  • Oregon Health & Science University, Portland, Oregon, USA.

Förderung

  • Medtronic Inc

Zitieren

APA

Zahr, F., Ramlawi, B., Reardon, M. J., Deeb, G. M., Yakubov, S. J., Song, H. K., Kleiman, N. S., Chetcuti, S. J., Gada, H., Mumtaz, M., Leung, S., Merhi, W., Rovin, J. D., DeFrain, M., Muppala, M., Kauten, J., Rajagopal, V., Huang, J., Ito, S., & Forrest, J. K. (2024). 3-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2024.05.017

Vancouver

Zahr F, Ramlawi B, Reardon MJ, Deeb GM, Yakubov SJ, Song HK, et al. 3-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study. JACC: Cardiovascular Interventions. 2024. doi:10.1016/j.jcin.2024.05.017

BibTeX
@article{Zahr2024,
  author = {Zahr, Firas and Ramlawi, Basel and Reardon, Michael J and Deeb, G Michael and Yakubov, Steven J and Song, Howard K and Kleiman, Neal S and Chetcuti, Stanley J and Gada, Hemal and Mumtaz, Mubashir and Leung, Stephane and Merhi, William and Rovin, Joshua D and DeFrain, Michael and Muppala, Murali and Kauten, James and Rajagopal, Vivek and Huang, Jiang and Ito, Saki and Forrest, John K},
  title = {3-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study},
  journal = {JACC: Cardiovascular Interventions},
  year = {2024},
  doi = {10.1016/j.jcin.2024.05.017}
}
Kostenlos starten →